Cargando…
Immune Infiltration in Invasive Lobular Breast Cancer
BACKGROUND: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathol...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037125/ https://www.ncbi.nlm.nih.gov/pubmed/29471435 http://dx.doi.org/10.1093/jnci/djx268 |
_version_ | 1783338284457394176 |
---|---|
author | Desmedt, Christine Salgado, Roberto Fornili, Marco Pruneri, Giancarlo Van den Eynden, Gert Zoppoli, Gabriele Rothé, Françoise Buisseret, Laurence Garaud, Soizic Willard-Gallo, Karen Brown, David Bareche, Yacine Rouas, Ghizlane Galant, Christine Bertucci, François Loi, Sherene Viale, Giuseppe Di Leo, Angelo Green, Andrew R Ellis, Ian O Rakha, Emad A Larsimont, Denis Biganzoli, Elia Sotiriou, Christos |
author_facet | Desmedt, Christine Salgado, Roberto Fornili, Marco Pruneri, Giancarlo Van den Eynden, Gert Zoppoli, Gabriele Rothé, Françoise Buisseret, Laurence Garaud, Soizic Willard-Gallo, Karen Brown, David Bareche, Yacine Rouas, Ghizlane Galant, Christine Bertucci, François Loi, Sherene Viale, Giuseppe Di Leo, Angelo Green, Andrew R Ellis, Ian O Rakha, Emad A Larsimont, Denis Biganzoli, Elia Sotiriou, Christos |
author_sort | Desmedt, Christine |
collection | PubMed |
description | BACKGROUND: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathological and outcome variables in ILC, and to compare them with IDC. METHODS: We considered two patient series with TIL data: a multicentric retrospective series (n = 614) and the BIG 02-98 study (n = 149 ILC and 807 IDC). We compared immune subsets identified by immuno-histochemistry in the ILC (n = 159) and IDC (n = 468) patients from the Nottingham series, as well as the CIBERSORT immune profiling of the ILC (n = 98) and IDC (n = 388) METABRIC and The Cancer Genome Atlas patients. All ILC/IDC comparisons were done in estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative tumors. All statistical tests were two-sided. RESULTS: TIL levels were statistically significantly lower in ILC compared with IDC (fold-change = 0.79, 95% confidence interval = 0.70 to 0.88, P < .001). In ILC, high TIL levels were associated with young age, lymph node involvement, and high proliferative tumors. In the univariate analysis, high TIL levels were associated with worse prognosis in the retrospective and BIG 02-98 lobular series, although they did not reach statistical significance in the latter. The Nottingham series revealed that the levels of intratumoral but not total CD8(+) were statistically significantly lower in ILC compared with IDC. Comparison of the CIBERSORT profiles highlighted statistically significant differences in terms of immune composition. CONCLUSIONS: This study shows differences between the immune infiltrates of ER-positive/HER2-negative ILC and IDC in terms of prevalence, levels, localization, composition, and clinical associations. |
format | Online Article Text |
id | pubmed-6037125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60371252018-07-12 Immune Infiltration in Invasive Lobular Breast Cancer Desmedt, Christine Salgado, Roberto Fornili, Marco Pruneri, Giancarlo Van den Eynden, Gert Zoppoli, Gabriele Rothé, Françoise Buisseret, Laurence Garaud, Soizic Willard-Gallo, Karen Brown, David Bareche, Yacine Rouas, Ghizlane Galant, Christine Bertucci, François Loi, Sherene Viale, Giuseppe Di Leo, Angelo Green, Andrew R Ellis, Ian O Rakha, Emad A Larsimont, Denis Biganzoli, Elia Sotiriou, Christos J Natl Cancer Inst Articles BACKGROUND: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathological and outcome variables in ILC, and to compare them with IDC. METHODS: We considered two patient series with TIL data: a multicentric retrospective series (n = 614) and the BIG 02-98 study (n = 149 ILC and 807 IDC). We compared immune subsets identified by immuno-histochemistry in the ILC (n = 159) and IDC (n = 468) patients from the Nottingham series, as well as the CIBERSORT immune profiling of the ILC (n = 98) and IDC (n = 388) METABRIC and The Cancer Genome Atlas patients. All ILC/IDC comparisons were done in estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative tumors. All statistical tests were two-sided. RESULTS: TIL levels were statistically significantly lower in ILC compared with IDC (fold-change = 0.79, 95% confidence interval = 0.70 to 0.88, P < .001). In ILC, high TIL levels were associated with young age, lymph node involvement, and high proliferative tumors. In the univariate analysis, high TIL levels were associated with worse prognosis in the retrospective and BIG 02-98 lobular series, although they did not reach statistical significance in the latter. The Nottingham series revealed that the levels of intratumoral but not total CD8(+) were statistically significantly lower in ILC compared with IDC. Comparison of the CIBERSORT profiles highlighted statistically significant differences in terms of immune composition. CONCLUSIONS: This study shows differences between the immune infiltrates of ER-positive/HER2-negative ILC and IDC in terms of prevalence, levels, localization, composition, and clinical associations. Oxford University Press 2018-02-20 /pmc/articles/PMC6037125/ /pubmed/29471435 http://dx.doi.org/10.1093/jnci/djx268 Text en © The Author(s) 2018. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Articles Desmedt, Christine Salgado, Roberto Fornili, Marco Pruneri, Giancarlo Van den Eynden, Gert Zoppoli, Gabriele Rothé, Françoise Buisseret, Laurence Garaud, Soizic Willard-Gallo, Karen Brown, David Bareche, Yacine Rouas, Ghizlane Galant, Christine Bertucci, François Loi, Sherene Viale, Giuseppe Di Leo, Angelo Green, Andrew R Ellis, Ian O Rakha, Emad A Larsimont, Denis Biganzoli, Elia Sotiriou, Christos Immune Infiltration in Invasive Lobular Breast Cancer |
title | Immune Infiltration in Invasive Lobular Breast Cancer |
title_full | Immune Infiltration in Invasive Lobular Breast Cancer |
title_fullStr | Immune Infiltration in Invasive Lobular Breast Cancer |
title_full_unstemmed | Immune Infiltration in Invasive Lobular Breast Cancer |
title_short | Immune Infiltration in Invasive Lobular Breast Cancer |
title_sort | immune infiltration in invasive lobular breast cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037125/ https://www.ncbi.nlm.nih.gov/pubmed/29471435 http://dx.doi.org/10.1093/jnci/djx268 |
work_keys_str_mv | AT desmedtchristine immuneinfiltrationininvasivelobularbreastcancer AT salgadoroberto immuneinfiltrationininvasivelobularbreastcancer AT fornilimarco immuneinfiltrationininvasivelobularbreastcancer AT prunerigiancarlo immuneinfiltrationininvasivelobularbreastcancer AT vandeneyndengert immuneinfiltrationininvasivelobularbreastcancer AT zoppoligabriele immuneinfiltrationininvasivelobularbreastcancer AT rothefrancoise immuneinfiltrationininvasivelobularbreastcancer AT buisseretlaurence immuneinfiltrationininvasivelobularbreastcancer AT garaudsoizic immuneinfiltrationininvasivelobularbreastcancer AT willardgallokaren immuneinfiltrationininvasivelobularbreastcancer AT browndavid immuneinfiltrationininvasivelobularbreastcancer AT barecheyacine immuneinfiltrationininvasivelobularbreastcancer AT rouasghizlane immuneinfiltrationininvasivelobularbreastcancer AT galantchristine immuneinfiltrationininvasivelobularbreastcancer AT bertuccifrancois immuneinfiltrationininvasivelobularbreastcancer AT loisherene immuneinfiltrationininvasivelobularbreastcancer AT vialegiuseppe immuneinfiltrationininvasivelobularbreastcancer AT dileoangelo immuneinfiltrationininvasivelobularbreastcancer AT greenandrewr immuneinfiltrationininvasivelobularbreastcancer AT ellisiano immuneinfiltrationininvasivelobularbreastcancer AT rakhaemada immuneinfiltrationininvasivelobularbreastcancer AT larsimontdenis immuneinfiltrationininvasivelobularbreastcancer AT biganzolielia immuneinfiltrationininvasivelobularbreastcancer AT sotiriouchristos immuneinfiltrationininvasivelobularbreastcancer |